A carregar...
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
Ibrutinib is a Bruton tyrosine kinase inhibitor that is approved by the FDA for the treatment of mantle cell lymphoma and other hematological malignancies. Bruton tyrosine kinases promote platelet aggregation, and, therefore, bleeding is a common side effect of ibrutinib. At least half of patients t...
Na minha lista:
| Publicado no: | Cureus |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cureus
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7377008/ https://ncbi.nlm.nih.gov/pubmed/32714681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.8743 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|